About: Comparison of different serological assays for SARS-CoV-2 in real life

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of different serological assays for SARS-CoV-2 in real life Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparison of different serological assays for SARS-CoV-2 in real life
Creator	Brochot, Etienne Castelain, Sandrine Duverlie, Gilles François, Catherine Demey, Baptiste Handala, Lynda
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: The emergence of the global SARS-CoV-2 pandemic required the rapid and large-scale deployment of PCR and serological tests in different formats. OBJECTIVES: Real-life evaluation of these tests is needed. Using 168 samples from patients hospitalized for COVID-19, non-hospitalized patients but infected with SARS-CoV-2, patients participating in screening campaigns, and samples from patients with a history of other seasonal coronavirus infections, we evaluated the clinical performance of 5 serological assays widely used worldwide (WANTAI®, BIORAD®, EUROIMMUN®, ABBOTT® and LIAISON®). RESULTS: For hospitalized patients, all these assays showed a sensitivity of 100 % from day 9 after the symptoms onset. On the other hand, sensitivity was much lower for patients who did not require hospitalization for COVID-19 confirmed by PCR (from 91.6 % for WANTAI® to 69 % for LIAISON®). These differences do not seem to be due to the antigens chosen by the manufacturers but more to the test formats (IgG detection versus total antibodies). In addition, more than 50 days after a positive PCR for CoV-2-SARS the proportion of positive patients seem to decrease. We did not observe any significant cross-reactions for these techniques with the four other seasonal coronaviruses. CONCLUSION: In conclusion, the evaluation and knowledge of the serological tests used is important and should require an optimized strategy adaptation of the analysis laboratories to best meet patient’s expectations in the face of this health crisis.
has issue date	2020-08-02(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104569
bibo:pmid	32769023
has license	no-cc
sha1sum (hex)	6d275c79f523e6db51553c77087e20cf39243d5e
schema:url	https://doi.org/10.1016/j.jcv.2020.104569
resource representing a document's title	Comparison of different serological assays for SARS-CoV-2 in real life
has PubMed Central identifier	PMC7396207
has PubMed identifier	32769023
schema:publication	J Clin Virol
resource representing a document's body	covid:6d275c79f523e6db51553c77087e20cf39243d5e#body_text
is schema:about of	named entity 'formats' named entity 'coronavirus' named entity 'EMERGENCE' named entity 'SARS-COV-2' named entity 'REAL' named entity 'SCREENING' named entity 'USED' named entity 'RAPID' named entity 'THESE' named entity 'SCALE' named entity 'USING' named entity 'pandemic' named entity 'infected' named entity 'PCR' named entity 'infections' named entity 'serological tests' named entity 'SARS-CoV-2' named entity 'serological' named entity 'serological' named entity 'receptor binding domain' named entity 'Serological tests' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'SARS' named entity 'IgM' named entity 'Antibody testing' named entity 'COVID' named entity 'serum samples' named entity 'IgG' named entity 'sero' named entity 'Antibody tests' named entity 'antibodies' named entity 'COVID-19' named entity 'serology' named entity 'immunoglobulin' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'acute disease' named entity 'PCR' named entity 'COVID' named entity 'antigenic' named entity 'clinical virology' named entity 'infection' named entity 'serological tests' named entity 'PCR' named entity 'institutional review board' named entity 'SARS-CoV-2' named entity 'antigenic' named entity 'serum' named entity 'antigen' named entity 'nasopharyngeal' named entity 'cellular immunity' named entity 'IgA' named entity 'SARS-CoV-2' named entity 'CLIA' named entity 'infection' named entity 'serological tests' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'enzyme-linked immunosorbent assays' named entity 'SARS-CoV-2' named entity 'chemiluminescent' named entity 'viruses' named entity 'humoral immunity' named entity 'epidemiological data' named entity 'immunoglobulins' named entity 'coronavirus' named entity 'coronaviruses' named entity 'PCR' named entity 'neutralizing antibodies' named entity 'antibodies' named entity 'antigens' named entity 'serological tests' named entity 'serological tests' named entity 'serological tests' named entity 'contact tracing'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software